| Scott Thomas Robinson, MD | |
|
92 Campus Dr Ste D, Scarborough, ME 04074-7229 | |
| (040) 742-0766 | |
| Not Available |
| Full Name | Scott Thomas Robinson |
|---|---|
| Gender | Male |
| Speciality | Vascular Surgery |
| Experience | 10 Years |
| Location | 92 Campus Dr Ste D, Scarborough, Maine |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1457765265 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Uf Health Shands Hospital | Gainesville, FL | Hospital |
| Maine Medical Center | Portland, ME | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Florida Clinical Practice Association | 0345146254 | 1636 |
| Mainehealth | 7517860588 | 2067 |
News Archive
Surgery to remove localized tumors is the only reliable way to cure lung cancer, the most prevalent cause of cancer-related deaths in both men and women. The most common operation performed to remove these cancers is a lobectomy (removal of an anatomic portion of lung). Thoracic surgeons at Rush University Medical Center perform the largest number of these operations of any surgical group in Chicago and in most cases use minimally invasive techniques that speed recovery.
Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.
Researchers at the University of Gothenburg in Sweden, together with their colleagues at the Barcelona Beta Research Centre in Spain, the University Medical Centre in Ljubljana, Slovenia, and the University of Paris, have found new forms of tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop.
Cubist Pharmaceuticals, Inc. today announced the early closing of enrollment in its ecallantide Phase 2 program. Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery, is now known as CB-500,929. After a regularly scheduled review meeting, the Data Safety Monitoring Board (DSMB) contacted the company to recommend a temporary suspension in enrollment in one of the CB-500,929 trials, CONSERV-2.
› Verified 5 days ago
| Entity Name | Florida Clinical Practice Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063463768 PECOS PAC ID: 0345146254 Enrollment ID: O20031211000099 |
News Archive
Surgery to remove localized tumors is the only reliable way to cure lung cancer, the most prevalent cause of cancer-related deaths in both men and women. The most common operation performed to remove these cancers is a lobectomy (removal of an anatomic portion of lung). Thoracic surgeons at Rush University Medical Center perform the largest number of these operations of any surgical group in Chicago and in most cases use minimally invasive techniques that speed recovery.
Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.
Researchers at the University of Gothenburg in Sweden, together with their colleagues at the Barcelona Beta Research Centre in Spain, the University Medical Centre in Ljubljana, Slovenia, and the University of Paris, have found new forms of tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop.
Cubist Pharmaceuticals, Inc. today announced the early closing of enrollment in its ecallantide Phase 2 program. Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery, is now known as CB-500,929. After a regularly scheduled review meeting, the Data Safety Monitoring Board (DSMB) contacted the company to recommend a temporary suspension in enrollment in one of the CB-500,929 trials, CONSERV-2.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott Thomas Robinson, MD 92 Campus Dr Ste D, Scarborough, ME 04074-7229 Ph: (040) 742-0766 | Scott Thomas Robinson, MD 92 Campus Dr Ste D, Scarborough, ME 04074-7229 Ph: (040) 742-0766 |
News Archive
Surgery to remove localized tumors is the only reliable way to cure lung cancer, the most prevalent cause of cancer-related deaths in both men and women. The most common operation performed to remove these cancers is a lobectomy (removal of an anatomic portion of lung). Thoracic surgeons at Rush University Medical Center perform the largest number of these operations of any surgical group in Chicago and in most cases use minimally invasive techniques that speed recovery.
Cell Therapeutics, Inc. today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis.
Researchers at the University of Gothenburg in Sweden, together with their colleagues at the Barcelona Beta Research Centre in Spain, the University Medical Centre in Ljubljana, Slovenia, and the University of Paris, have found new forms of tau protein that become abnormal in the very early stages of Alzheimer's disease before cognitive problems develop.
Cubist Pharmaceuticals, Inc. today announced the early closing of enrollment in its ecallantide Phase 2 program. Ecallantide, in development as therapy to reduce bleeding in on-pump cardiac surgery, is now known as CB-500,929. After a regularly scheduled review meeting, the Data Safety Monitoring Board (DSMB) contacted the company to recommend a temporary suspension in enrollment in one of the CB-500,929 trials, CONSERV-2.
› Verified 5 days ago
John Birknes, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 49 Spring St, Scarborough, ME 04074 Phone: 207-885-0011 | |
Elizabeth S.m. Desjardin, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Dr Unit 121, Scarborough, ME 04074 Phone: 207-396-7760 Fax: 207-396-8500 | |
Dr. Douglas L Jicha, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 306 Us Route 1, Bldg C, Scarborough, ME 04074 Phone: 207-885-5742 Fax: 207-885-1494 | |
Dr. Paige Teller, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 100 Campus Dr, Suite 121, Scarborough, ME 04074 Phone: 207-396-7788 Fax: 207-396-8500 | |
Dr. Lily Wang, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 92 Campus Dr Ste D, Scarborough, ME 04074 Phone: 207-661-2087 | |
Dr. John G Carson, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 92 Campus Dr Ste D, Scarborough, ME 04074 Phone: 207-662-8900 |